October 19, 2022 Atomic Spectroscopy Licensing, IP, and Legal Product Launch Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 Read more
October 18, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022 Read more
October 12, 2022 Uncategorized Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use Read more
October 12, 2022 Product Launch Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA) Read more
October 11, 2022 Product Launch Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma Read more
October 5, 2022 Product Launch Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022 Read more
October 4, 2022 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU Read more
October 3, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023 Read more
September 19, 2022 Uncategorized European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss Read more
